Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;116(6):1521-1524.
doi: 10.1002/cpt.3443. Epub 2024 Sep 17.

External Controls to Study Treatment Effects in Rare Diseases: Challenges and Future Directions

Janick Weberpals  1 , Shirley V Wang  1
Affiliations
Review

External Controls to Study Treatment Effects in Rare Diseases: Challenges and Future Directions

Janick Weberpals et al. Clin Pharmacol Ther. 2024 Dec.

Abstract

Regulators increasingly rely on real-world evidence generated from routine-care health data to evaluate novel therapies. Particularly, external control arms are increasingly used to supplement and contextualize efficacy and safety claims of single arm clinical trials for rare disease therapies. However, there are a number of methodological issues that may affect the validity of results derived from such comparisons. In this mini-review, we briefly summarize frequently used approaches and outline some of the most important criticisms and paths forward.

PubMed Disclaimer

References

    1. Sola‐Morales, O. et al. Effectively leveraging RWD for external controls: a systematic literature review of regulatory and HTA decisions. Clin. Pharmacol. Ther. 114, 325–355 (2023).
    1. Wang, S.V. et al. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA 329, 1376–1385 (2023).
    1. Heyard, R., Held, L., Schneeweiss, S. & Wang, S.V. Design differences and variation in results between randomised trials and non‐randomised emulations: meta‐analysis of RCT‐DUPLICATE data. BMJ Med. 3, e000709 (2024).
    1. Zou, K.H. et al. The next horizon of drug development: external control arms and innovative tools to enrich clinical trial data. Ther. Innov. Regul. Sci. 58, 443–455 (2024).
    1. Vaghela, S., Tanni, K.A., Banerjee, G. & Sikirica, V. A systematic review of real‐world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases. Orphanet J. Rare Dis. 19, 117 (2024).

LinkOut - more resources